Translational Science

Overview of Current Studies

A subgroup of PAN-TB members signed a joint development agreement in 2022 supporting the progression of two investigational TB combination treatment regimens into phase 2 clinical development. The collaboration will evaluate whether the novel regimens, which combine registered products and new chemical entities (NCEs), can effectively treat all forms of active pulmonary TB using substantially shorter treatment durations than existing drug regimens.

The five antimicrobial agents to be evaluated under the new JDA, and the organizations contributing them, include:

• Bedaquiline; registered product for multidrug-resistant TB, Janssen Pharmaceutica NV, part of the Janssen Pharmaceutical Companies of Johnson & Johnson, and NCE for drug-sensitive TB, TB Alliance
• Delamanid; registered product, Otsuka Pharmaceutical Co., Ltd.
• Pretomanid; registered product, TB Alliance
• Quabodepistat (formerly, OPC-167832); NCE, Otsuka Pharmaceutical Co., Ltd.
• Sutezolid; NCE, TB Alliance, Medicines Patent Pool, Bill & Melinda Gates Medical Research Institute

The two investigational drug regimen combinations to be evaluated include:

• DBQS – delamanid, bedaquiline, quabodepistat and sutezolid
• PBQS – pretomanid, bedaquiline, quabodepistat and sutezolid